Abstract
Modification of proteins by nonenzymatic glycation is one of the underlying factors that contribute to the development of the complications of diabetes. Human serum albumin (HSA) is one of the major targets of interaction with glucose through the Maillard reaction. The effects of 1 and 5 mg/ml glucose concentrations, which are consistent with blood glucose levels found in diabetic patients, on human serum albumin were studied by circular dichroism and fluorescence spectroscopy in sodium phosphate buffer, pH 7.4. Partial denaturation and changes in the structural integrity of HSA are caused by glycation at lower (1 mg/ml) and higher (5 mg/ml) concentrations of glucose. To study the relationship between structure and function, we investigated the interaction of L-tryptophan (L-Trp) with glycated and nonglycated HSA. The results showed that L-Trp, as the only free amino acid that substantially binds to HSA, has a lower affinity for the glycated form (especially at low concentrations of glucose) than for non-glycated HSA.
Keywords: Conformational change, Glycation, HSA, L-Trp binding
Protein & Peptide Letters
Title: Spectroscopic Studies of the Effects of Glycation of Human Serum Albumin on L-Trp Binding
Volume: 14 Issue: 1
Author(s): Abolfazl Barzegar, Ali A. Moosavi-Movahedi, Naghmeh Sattarahmady, Mohammad A. Hosseinpour-Faizi, Mohammad Aminbakhsh, Faizan Ahmad, Ali A. Saboury, Mohammad R. Ganjali and Parviz Norouzi
Affiliation:
Keywords: Conformational change, Glycation, HSA, L-Trp binding
Abstract: Modification of proteins by nonenzymatic glycation is one of the underlying factors that contribute to the development of the complications of diabetes. Human serum albumin (HSA) is one of the major targets of interaction with glucose through the Maillard reaction. The effects of 1 and 5 mg/ml glucose concentrations, which are consistent with blood glucose levels found in diabetic patients, on human serum albumin were studied by circular dichroism and fluorescence spectroscopy in sodium phosphate buffer, pH 7.4. Partial denaturation and changes in the structural integrity of HSA are caused by glycation at lower (1 mg/ml) and higher (5 mg/ml) concentrations of glucose. To study the relationship between structure and function, we investigated the interaction of L-tryptophan (L-Trp) with glycated and nonglycated HSA. The results showed that L-Trp, as the only free amino acid that substantially binds to HSA, has a lower affinity for the glycated form (especially at low concentrations of glucose) than for non-glycated HSA.
Export Options
About this article
Cite this article as:
Barzegar Abolfazl, Moosavi-Movahedi A. Ali, Sattarahmady Naghmeh, Hosseinpour-Faizi A. Mohammad, Aminbakhsh Mohammad, Ahmad Faizan, Saboury A. Ali, Ganjali R. Mohammad and Norouzi Parviz, Spectroscopic Studies of the Effects of Glycation of Human Serum Albumin on L-Trp Binding, Protein & Peptide Letters 2007; 14 (1) . https://dx.doi.org/10.2174/092986607779117191
DOI https://dx.doi.org/10.2174/092986607779117191 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Temperature and Ionic Strength on Structure and Chaperone Activity of Glycated and Non-Glycated Alpha-Crystallins
Protein & Peptide Letters Epigenetic Alterations in DNA and Histone Modifications Caused by Depression and Antidepressant Drugs: Lessons from the Rodent Models
Current Pharmaceutical Design Fanconi-Bickel Syndrome - A Congenital Defect of Facilitative Glucose Transport
Current Molecular Medicine Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication
Current Drug Safety Biomarkers of Cardiovascular Risk in Haemodialysis Patients
Current Pharmaceutical Design Primary Prevention of Cardiovascular Risk in Octogenarians by Risk Factors Control
Current Hypertension Reviews Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease
Current Molecular Pharmacology Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry Therapeutical Relevance of MAP-Kinase Inhibitors in Renal Diseases: Current Knowledge and Future Clinical Perspectives
Current Medicinal Chemistry Reproduction in Couples with Chronic Viral Infections
Current Women`s Health Reviews Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Obstetric Anaesthesia and Obesity
Current Women`s Health Reviews Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia
Current Neuropharmacology Cancer and the Endogenous “Pineal Clock”: A Means of Early Diagnosis and Successful Treatment as Well as Prevention of Cancers
Current Aging Science The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle
Current Hypertension Reviews Sympathetic and Baroreflex Function in Hypertension: Implications for Current and New Drugs
Current Pharmaceutical Design Toxic Effects of Aflatoxin B1 on Embryonic Development of Zebrafish (Danio rerio): Potential Activity of Piceatannol Encapsulated Chitosan/poly (Lactic Acid) Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design Hyperglycemia Regulates TXNIP/TRX/ROS Axis via p38 MAPK and ERK Pathways in Pancreatic Cancer
Current Cancer Drug Targets